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Abstract. Generally, bioequivalence (BE) studies of drug products for pediatric patients
are conducted in adults due to ethical reasons. Given the lack of direct BE assessment in
pediatric populations, the aim of this work is to develop a database of BE and relative
bioavailability (relative BA) studies conducted in pediatric populations and to enable the
identification of risk factors associated with certain drug substances or products that may lead
to failed BE or different pharmacokinetic (PK) parameters in relative BA studies in
pediatrics. A literature search from 1965 to 2020 was conducted in PubMed, Cochrane
Library, and Google Scholar to identify BE studies conducted in pediatric populations and
relative BA studies conducted in pediatric populations. Overall, 79 studies covering 37 active
pharmaceutical ingredients (APIs) were included in the database: 4 bioequivalence studies
with data that passed BE evaluations; 2 studies showed bioinequivalence results; 34 relative
BA studies showing comparable PK parameters, and 39 relative BA studies showing
differences in PK parameters between test and reference products. Based on the above
studies, common putative risk factors associated with differences in relative bioavailability
(DRBA) in pediatric populations include age-related absorption effects, high inter-individual
variability, and poor study design. A database containing 79 clinical studies on BE or relative
BA in pediatrics has been developed. Putative risk factors associated with DRBA in pediatric
populations are summarized.
KEY WORDS: bioequivalence; oral product; pediatric; relative bioavailability; risk factors.
INTRODUCTION
To ensure therapeutic equivalency, the rate and extent of
drug absorption should not be significantly different between
generic products and their corresponding reference products
when administered at the same molar dose of the therapeutic
ingredient under similar experimental conditions in either a
single dose or multiple doses (1, 2). BE studies form an
integral part in generic and new drug products approval
process. For assessing BE, PK endpoints such as peak plasma
concentration (Cmax) and area under the plasma concentra-
tion time curve (AUC), which reflect the rate and extent of
drug absorption, are used. According to the U.S. Food and
Drug Administration (U.S. FDA), the test and reference
products are considered BE when the 90% confidence
interval of the geometric mean ratios of Cmax, AUC0–t, and
AUC0–∞ between the test and reference formulations are
within the BE acceptance region of 80–125% (3). Because the
purpose of a BE study is to draw a generalizable conclusion
about the test and reference products, BE studies are most
often conducted in healthy adult populations. BE studies are
designed to compare the test and reference products with the
same dosage form in the most sensitive, accurate, and
reproducible way. From this evidence, regulators then con-
clude that the test and reference products can be substituted
for all patient populations described in the product label.
Due to the need for age-appropriate medicines with
flexible dosing options, pediatric formulations can differ from
the product used in adults (e.g., use of a suspension rather
than a tablet); thus, a change in relative BA may be possible.
Indeed, the pediatric formulation is designed to achieve the
target systemic exposure in the population of interest thus a
change in PK exposure may be attributable to formulation
design. The purpose of relative BA studies, as distinct from
BE studies, is to compare the rate and extent of drug
absorption between two pharmaceutical dosage forms (e.g.,
a novel pediatric formulation) and a reference product (e.g.,
adult formulation); they are usually conducted in healthy
adults (4). Moreover, there is no formal statistical assessment
associated with relative BA studies to demonstrate whether
they “pass” or “fail” yet sometimes BE acceptance limits are
applied to these studies (5). Because relative BA studies are
often designed to be descriptive and intended to inform
instructions for product use, it is more common to find a
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relative BA study conducted in a pediatric population than to
find a BE study conducted in a pediatric population.
Drug absorption differs in pediatric populations com-
pared to adults due to differences in gastrointestinal (GI)
physiology and anatomy (6, 7). This has led to concerns about
comparing pediatric drug product formulations in healthy
adults to inform treatment in pediatric populations. Healthy
adults are often used as a surrogate population to test the BE
of generic and reference pediatric products and to test
relative BA for novel pediatric formulations via a two-way
crossover design. Thus, the results from adult population
studies (i.e., BE and relative BA studies) are presumed to be
the same as in the pediatric population. However, there is a
need to identify drug substance or drug products under
certain circumstances at risk of discrepancy with the above
assumption, so further control strategy/justification can be
applied to these products.
When a relative BA study is conducted in adults, the
magnitude of difference between the two formulations is
often directly applied to the pediatric population to decide
the appropriate dose to administer. This was the case with the
lamivudine ARROW trial (8), which compared split scored-
tablets and solutions of lamivudine in children and showed
that the exposure was approximately 55% higher with the
tablet compared to the liquid in children yet the two
formulations were equivalent in an adult population (9).
The causative agent in this case was presumed to be the
sorbitol content of the oral liquid, which influences the GI
transit time (10). Thus, an understanding of pediatric
anatomy and physiology is required to better predict the
impact of drug product dissolution and drug substance
solubility on drug absorption. For instance, several reports
showed changes in the Biopharmaceutics Classification Sys-
tem (BCS) class for the same drug substance in pediatric
compared to adult populations (11–15). A number of risk
factors linked to bioinequivalence have been identified from
the literature, some examples include: physiological factors
(absorption-distribution-metabolism-excretion, ADME ef-
fects) (16), formulation effects (10), disease progression and
other disease-related effects (17), and poor study design (18).
Despite the notion that BE established in adults is
generally extrapolatable to pediatric populations, there is still
a need to identify putative risk factors associated with this
concept. This study intended to collect available data from
literature that reported bioinequivalence or disparities in PK
profiles in BE and relative BA studies conducted in pediatric
populations to improve the understanding and identification
of any common risk factors that relate to the difference in PK
observed.
METHODS
We systematically searched the literature in PubMed
(19), Cochrane Library (20), and Google Scholar (21) for
potentially relevant studies that assessed relative BA and BE
studies in a pediatric population. To collate the largest
possible datasets, different search keywords were identified
from the literature such as: “bioequivalence” (22); “relative
bioavailability” (16); “failed bioequivalence” (23); “lack of
bioequivalence” (24); “bioinequivalence” (25), and “non-
bioequivalent” (26). In this paper, we used the term
“bioinequivalence” to describe cases where the BE criteria
were not met and to encompass lack of BE, failed BE, or
non-bioequivalent. The combination of search keywords
listed in Table I were used to capture data from pediatric
populations (aged from 0 to 17 years).
Any duplicate studies identified in more than one
database were excluded from the list with the help of
EndNote and manual review.
The inclusion and exclusion criteria used to identify
relevant high-quality studies are listed in Table II. Two
independent reviewers applied these criteria to the identified
literature to minimize bias.
A standardized data collection tool was constructed
using Microsoft Excel to capture the extracted information
under different categories as provided in Table III.
In this paper, we use the term, difference in relative
bioavailability (DRBA), to refer to either failed BE studies or
studies that demonstrated a difference in relative bioavail-
ability. In this paper, we extracted the reasons that the
original authors provided for the change in exposure noted
within the studies. This means that the ADME-related
differences were those reported in the original studies and it
may well be an interplay between the formulation and the
absorption This could also include links to secondary
references where authors interpreted their data in the context
of wider literature.
The physicochemical drug properties, including molecu-
lar weight, Log P, and water solubility, as well as oral BA
(%), were extracted from the Drug Bank database (27).
Narrow therapeutic index (NTI) data for the drugs where
“small differences in dose or blood concentration may lead to
dose and blood concentration dependent, serious therapeutic
failures or adverse drug reactions that are life-threatening or
result in persistent or significant disability or incapacity” (28)
were identified using information within product-specific
guidances (PSG) where the U.S. FDA identified drugs as
NTI (29). The BCS classification for those drugs included was
reported from the NICHD-FDA report (30) and from specific
publications relating to the development of provisional
pediatric BCS systems (6, 14, 15, 31). Both adult and pediatric
BCS classifications are reported to enable comparison within
these populations and to identify those drugs where the BCS
classification changes between adult and pediatric
populations.
RESULTS
A total of 79 clinical studies containing data from
pediatric populations were identified using the search terms
listed above and applying the inclusion and exclusion criteria
(Supplementary Material 1, database for relative BA and BE
studies in pediatrics). Subsequently, a total of 41 studies with
DRBA results between test and reference products remained
for further analysis (Supplementary Material 2, risk factor
summary). The 41 studies included 2 BE studies and 39
relative BA studies that showed disparities in PK properties
when test and reference produces were compared.
These 41 (2 BE and 39 relative BA) studies were
interrogated to identify the reported putative risk factors that
could be responsible for the failure of BE in pediatrics. A
summary of these risk factors is shown in Table IV.
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Further details and examples of studies are described in
the text below.
Physiological Factors (ADME Effect)
Age-Related Absorption Effects
As listed in Table IV, 28 studies reported DRBA
attributed to age-related absorption (differences in absorp-
tion between pediatric and adult populations). Fifteen out of
28 studies reported multiple absorption-related risk factors (8,
32–45), including alterations in GI transit time or motility (8,
33, 36, 38, 40, 44), changes in GI fluid composition (37, 40),
and different levels of saturation for intestinal transporters/
metabolism (8, 42). Moreover, 11 of the studies from the list
of 28 reported factors are also related to the formulations
used (32, 34–41, 43, 45), and 5 also related to the drug
substance (8, 33, 38, 40, 44). It should be noted that a BE
study conducted as a crossover study would cancel out the
age-related effects on clearance and highlight those effects
that are related to formulation differences; however, due to
the limited crossover BE studies conducted in pediatric
populations, we summarized all the risk factors related to
applying clinical study results from adults to pediatric
populations. GI Transit. Altered GI transit time in chil-
dren as compared to adults was listed as a risk factor for
DRBA. For example, an emtricitabine capsule formulation
provided 20% higher plasma exposure compared to the
solution formulation in children reportedly due to the fact
that the GI transit time of the solution was shorter than that
of the capsule formulation (44).
The rapid GI transit in children has been implicated as a
risk factor for DRBA for drugs such as cyclosporine A (33,
36, 38). This risk factor is associated with formulation changes
that alter the rate of drug release (33, 36, 38, 46). In previous
studies conducted in adults, factors including bile flow, GI
motility, bowel length, and food intake and composition were
found to affect the absorption of certain cyclosporine
formulations (38) and phenytoin (40). There is an interplay
between formulation effects and GI transit, and if GI transit
time limits drug absorption, differences in formulation may
have impact on the absorption. Thus, the implications of
these effects in adult studies may increase in pediatric
populations (40).
In neonates and infants below the age of 6–8 months,
gastric emptying was found to be slower due to immaturity of
the neuroregulation of gastric motility (69). Evidence on
differences in GI transit between adults and children is
conflicting and there is very limited detailed information on
gastric emptying and small intestinal transit times in pediatric
populations (70, 71). There is evidence that shorter transit
times of solutions compared to solid dosage forms in adults
were observed from one study comparing solutions, small
pellets, and tablets in adults (72) and from a second study
comparing the pharmacokinetics of alendronate solution and
tablets (73). Thus, a change in formulation from solid to
liquid may be associated with shorter transit time in pediatric
populations; this is likely to be exacerbated for monolithic
controlled release tablets as their relative size may delay
Table I. Combination of Search Keywords Used To Identify Relevant Literature. Note for Google Scholar, We Omitted “OR” and “AND”
With the Keywords




“Lack of Bioequivalence” OR
“Bioinequivalence”
AND
To limit to a pediatric population “Infant” OR “Child” OR “Children” OR “Adolescent” OR “Pediatric”
AND
To limit to orally administered products “Oral drug”
Table II. Inclusion and Exclusion Criteria Used To Identify the Studies To Be Included in Further Analysis
I n c l u s i o n
criteria
• Studies conducted on U.S. FDA or European Medicines Agency (EMA) approved drugs for oral administration only.
• Studies must include data from pediatric populations.
• The studies must provide information on study design (e.g., randomized controlled, crossover design, and parallel design),
subjects information (age, weight, height, sex, origin, inclusion, or exclusion criteria), sample size, dose of the drugs (single or
multiple), washout period, study conditions (fasting or fed state), and clinical trials registration ID.
• BE studies must report the statistical analysis containing the 90% CIs (80–125%) or geometric mean ratios (0.8–1.25) for
both the test and reference medicines for the PK endpoints AUC and Cmax. Studies should also state whether they met the
BE criteria according to U.S. FDA or EMA guidelines.
• For relative BA studies, PK endpoints such as AUC and Cmax data are required for tested and reference products.
E x c l u s i o n
criteria
• Studies on drugs not administered orally.
• Studies reporting difference in relative bioavailability (DRBA) due to the presence of food or drinks or herb-drug
interactions or drug-drug interactions.
   57 Page 3 of 12The AAPS Journal          (2021) 23:57 
passage through the pyloric sphincter, as observed with a
quicker onset of action for multi-particulate formulations
compared to single unit tablets (74, 75). However, it should
be noted that there is currently no evidence on the relative
gastric emptying or intestinal transit time of liquid and solid
oral dosage forms in pediatric populations.
Saturation of GI Transporters. The authors reported that
oral administration of highly soluble drugs may lead to very
high local concentrations of active components in children
resulting in saturation of GI membrane influx or efflux
transporters leading to altered BA (8). For liquid dosage
forms, the drug is already homogenously dissolved or
dispersed within the solvent yet dissolution from solid oral
dosage forms can lead to regions of highly concentrated drug
in solution. The impact of high local concentrations saturating
GI membrane transporters was identified as a risk factor in
the higher exposure of lamivudine tablets compared to an
oral solution in children (8). Saturation of GI membrane
transporters was also identified for a BCS class 3/1 drug
sulfadoxine (76) as a risk factor in a study where there was a
32% reduction in the relative BA of sulfadoxine (in
combination with pyrimethamine) when the dose was dou-
bled in infants with malaria (42). Previously, the concept of
saturation of efflux transporters has been highlighted as a
theory yet not considered to be clinically relevant (77, 78);
thus, further research is required to better understand the
true likelihood of saturation of transporters in pediatric
populations leading to clinically significant changes.
Age-Related Distribution Effects
Two studies were identified with DRBA attributed to
differences in the volume of distribution (40, 47): one
specifically identified protein binding (40) and another study
identified intracellular drug transport as risk factor for DRBA
(47).
The volume of distribution of drugs has been reported to
change with age. In younger children, higher doses of
hydrophilic drugs are required because of the higher percent-
age of water content in their body; however, lower doses of
hydrophilic drugs are required in older children due to the
increased proportion of body fat (79). Neonates have lower
plasma protein bindings which may increase the fraction
unbound for certain highly protein bound drugs and lead to
higher plasma exposure (80).
Age-Related Metabolism or Clearance Effects
Fifteen studies were identified with DRBA due to
changes in metabolism or clearance (32–34, 36, 42, 43, 47–
50, 58–62). Differences in enzyme expression and activity can
result in altered metabolism of drug substance, which may
result in altered production or accumulation of the metabo-
lites. A classic example is gray baby syndrome where the
immaturity of hepatic UDP-glucuronyl transferase enzymes
in babies leads to accumulation of chloramphenicol metabo-
lites and subsequent toxicity (81).
Variability in genetic polymorphism associated with
certain metabolic pathways may increase the likelihood of
DRBA (82). This was implicated as a risk factor in a study on
lopinavir/ritonavir which are substrates of the multi-drug
resistance gene (MDR-1) and organic anion-transporting-
polypeptide (OATP) drug transporters as well as some
CYP450-based metabolism in the GI tract (47).
Risks for DRBA were also reported (in 1986) for
alternative phenytoin (generic tablets and capsules) in
epileptic children where dose-related saturation of hepatic
metabolizing enzymes or binding proteins could lead to
higher plasma concentrations as a result of the small change
in dose/exposure resulting in toxicity (49).
Since several other studies conducted in adults have
highlighted issues changing phenytoin brand (83) for reasons
including a change in excipients (from calcium sulfate to
lactose) (84); differences in the physicochemical properties of
excipients (85); differences in uniformity of content (86);
stability issues (86), and ethnic differences in metabolism
(87). Current advice in the UK is to remain on the same
brand of phenytoin where possible (88). In addition, as FDA
has concluded that phenytoin is an NTI drug (within the
product-specific guidance), thus the in vivo BE study should
be a fully replicated crossover design in order to scale
bioequivalence limits to the variability of the reference
product and meet the unscaled average BE criteria and
Table III. Details of Information Extracted From Each Study Identified Within the Literature Search
Study details Study title; URL link; study design (i.e., randomized controlled, parallel, or cross-over); sample size; dose
administered; single or multiple dose
Study population Age; healthy/diseased state; number of participants
Test and reference
products
Dosage form and strength of the test and reference products (i.e., tablet and capsule); pre-dosing manipulations (e.g.,
halving or quartering or crushing the tablets before administration)
Administration details Fasted/fed state; volume of water consumed (ml)
Study results 90% CIs (80–125%) or geometric mean ratios (0.8–1.25) for both the test and reference medicines for the PK
endpoints AUC and Cmax; statistics
Interpretations Authors interpretation of data on product equivalence (Yes/No)
R i s k f a c t o r s f o r
DRBA
Original authors’ reasons for DRBA stated in the paper
Clinical impact of
DRBA
Authors interpretation of data on clinical equivalence (Yes/No)
Miscellaneous details Clinical trials registration ID; remarks; reference
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compare test and reference product within-subject variability
(89).
Drug Substance and Formulations Effects
Drug Substance Effects
Five of the identified studies reported drug substance
properties (e.g., salt form, intrinsic solubility, and crystal
form) as factors associated with DRBA (34, 35, 39, 40, 51).
Here, “drug substance” refers to the active ingredient and
includes properties related to particle size, salt form, and
intrinsic solubility. For drugs such as rifampicin and tacroli-
mus, poor solubility has been highlighted as one of the
confounding reasons for DRBA (35, 51).
DRBA between hydrocortisone suspension (Cortef: 10
mg/ml, suspending agent-xanthan gum) and a tablet was
observed in 19 children; as a result, the liquid formulation was
recalled from the market (39). The liquid formulation in this
study contained hydrocortisone cypionate, an ester form of
hydrocortisone which is different from the free hydrocorti-
sone used in previous suspension formulation used in adult
study (90). In adult study, the suspension formulation of free
hydrocortisone showed higher absorption compared to the
tablets and a shorter half-life than hydrocortisone tablets;
they are not BE to each other either.
The crystal form plays an important role in the absorp-
tion of pharmaceutical active ingredient. The manufacturing
process of rifampicin (RMP) could result in the formation of
either polymorphic or amorphous state of RMP with eight-
fold difference in water solubility between the two states (91).
Consequently, RMP exposure was found to be 76% lower
among children who received the R-Cin® suspension com-
pared to Eremfat®. The study highlighted that the differences
in BA between the two suspension formulations were due to
the mixture of polymorphic forms of RMP in R-Cin® that
was not favorable for absorption (51). The solubility of any
material is dependent upon the volume and composition of
the solvent; there are known differences in the intestinal
fluids between adults and children thus the relative difference
in the formulation may not be directly transferable.
The particle size of sodium phenytoin can affect its oral
BA; three separate studies have demonstrated that smaller
particles dissolve more rapidly and have increased BA
compared to larger particles (34, 40, 92).
The intrinsic poor solubility of certain drugs can increase
risks of non-linear PK due to incomplete dissolution within
the GI tract (35, 49, 52, 63), especially for children whose GI
volume is less compared to adults (93).
Drug Product/Formulations Effects
Drug product effects may change the exposure to a drug
substance due to changes in dosage form (e.g., tablet versus
capsule or liquid oral formulation), drug release profiles (e.g.,
immediate or extended release or complex release formula-
tion), and formulation constituents (e.g., excipient effect).
Drug product effects are typically reflected in relative BA
studies.
From the relative BA studies identified, 12 studies
showed drug product effects on BA (32, 34–41, 43, 45, 63).
The magnitude of drug product effects may be amplified in
pediatric populations where differences in absorption relate
to factors such as GI motility where small formulation
changes can result in large PK differences as shown with
controlled release formulations (33, 38, 40, 44).
Neoral (microemulsion of cyclosporin A) was rapidly
absorbed in children producing a high peak level within 1 to
2 h of dosing. This observation was due to the increased
effective surface area achieved by the microemulsion com-
pared to a more conventional formulation (33, 36–38, 45).
Three studies reported DRBA due to excipient effects
(32, 34, 63). For extemporaneously prepared 6-
mercaptopurine (6-MP) liquid formulations, differences in
formulation constituents (excipients) and viscosity, and po-
tentially 6-MP could have contributed to the observed
variability in systemic drug availability from liquid formula-
tions (63). Lactose, which is an excipient widely used as a
Table IV. Summary of Stratification of Author’s Reported Reasons for Failed Pediatric BE and Relative BA Studies Identified Within This
Review. Note That Multiple Reasons May Have Been Listed for a Single Study





Age-related absorption effects (e.g., GI motility, GI fluid
volume or composition, and GI transit time)
28 (8, 26, 32–57)
Age-related distribution effects (e.g., protein binding) 2 (40, 47)




Drug substance effect (e.g., alternative salt or polymorphic form
of drug substance)
5 (34, 35, 39, 40, 51)
Drug product/formulation effects 12 (32, 34–41, 43, 45, 63)
Disease Age-related disease progression and other disease-related
effects
4 (26, 53, 63, 64)
Population
characteristics
High inter- and/or intra-individual variabilities 18 (33, 36–39, 41, 45–48, 50, 54, 55,
58, 61, 63, 65, 66)
Study design Non-equivalent dose effects 2 (39, 67)
Accuracy of administered dose 2 (60, 68)
Poor study design including small sample size 11 (35, 43, 44, 49, 51–53, 59, 62, 66,
67)
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filler or filler-binder in the manufacture of tablet and
capsules, could aid in moistening of the phenytoin particles
in tablet formulation and this enhanced the dissolution rate
followed by increase in absorption and plasma exposure (34).
Age-Related Disease Progression and Other Disease-Related
Effects
FDA’s Guidance for Industry: Providing Clinical Evi-
dence of Effectiveness for Human Drug and Biological
Products recommends that the efficacy data from adult
population can be extrapolated to pediatric population when
the course of the disease and the effects are sufficiently
similar (94). In our analysis, 4 studies attributed the DRBA
reported to differences in disease progression between adults
and children (26, 53, 63, 64). These diseases include HIV;
congenital hypothyroidism; malaria; epilepsy; attention deficit
hyperactivity disorder (ADHD), and organ transplant. For
example, in HIV-infected children, co-administration of
antibiotics with anti-HIV drugs have been reported to (i)
decrease the absorptive surface area of the intestine (95), (ii)
alter gut flora (96), (iii) cause local GI inflammation (97), (iv)
lead to fat malabsorption (98), and (v) cause diarrhea (99).
All of these effects were shown to alter the BA of the anti-
HIV zidovudine in children (100). In another example,
Synthroid and one of its generic L-T(4) versions were
observed to have a different pharmacodynamic response in
children (n = 36) suffering from congenital hypothyroidism
(CH) due to diminished thyroid reserve (26).
Population Characteristics
A total of 18 studies linked DRBA to population effects
from participants in the study. These population effects
include: high inter-individual variability within the study
population (33, 36–39, 41, 45–48, 54, 55, 58, 61, 63, 65, 66),
high intra-individual variability (45, 50, 63), or genetic
polymorphism associated with metabolism of drugs (47, 58,
65). The consequences of these population effects may
increase in the developing pediatric population. For example,
pediatric liver transplant recipients are known to show poor
and variable absorption of cyclosporin partly because of the
limited absorptive surface area associated with small bowel
lengths (36, 101), surgical bowel reconstruction, and also due
to higher rates of metabolism of cyclosporine (36, 55).
Study Design
Dosing issues and poor study design were listed as a risk
factor for DRBA in 15 studies, as detailed in Table IV.
Non-equivalent Dose and Accuracy of Administered Dose
Non-equivalent dose may play a role in the DRBA of the
tested medicines such as hydrocortisone and levothyroxine
(39, 67). In addition, extemporaneous preparation of products
such as hydrocortisone and nevirapine may make dose
accuracy within the test questionable (60, 68).
Poor Study Design Including Small Sample Size
Failure to meet BE criteria may occur as a result of
underpowered studies (102). Eleven studies reported DRBA
due to an underpowered study design (35, 43, 44, 49, 51–53,
59, 62, 66, 67).
Small sample size was a factor behind the DRBA
reported in 7 of the original 11 studies (43, 44, 51, 53, 59,
66, 67). One of the studies already highlighted recruited small
sample sizes (n = 2–10) due to the nature of study population,
for example, patients with organ transplant (59). Risk factors
of poor study design from the studies already identified
include: non-randomized study design (44, 62, 67, 103);
parallel study arms (35); retrospective study design (104);
methodology used in statistical results (e.g., partial AUC
calculations were not considered for complex release methyl-
phenidate formulations) (104), or baseline errors for endog-
enous molecules (e.g., levothyroxine (105)).
Further Analysis on BCS Classification of Drugs Showing
DRBA Results
The BCS classification of the drugs included in the
studies were reported as those based on adult data and those
relevant to the pediatric data as described in “METHODS.”
Table V summarizes the BCS classification and NTI of each
drug where DRBA was reported.
BCS 2 drugs were the most commonly reported with
DRBA, perhaps unsurprisingly as poor solubility is associated
with greater variability in plasma exposure (108, 109). The
proportion of BCS 2 drugs (55.5%) listed here was lower to
the proportion of BCS 2 drugs mentioned in a previous study
(based on AUC criteria in healthy, young volunteers) where
63% of drugs were BCS class 2 DRBA products (110).
Further Analysis on NTI Classification of Drugs Showing
DRBA Results
In this study, the NTI drugs made up 28% of those where
DRBAwas reported. The proportion of NTI drugs within this
study appears to be lower than the proportion previously
reported in a similar study (based on a small subset of
products from 2005 to 2008) (28% in this study compared to
56% in the previous study) (22) (111). However, it should be
noted that the previous study used a much smaller sample
size (n = 9 DRBA studies) where data mining was conducted
for 3 years and only 9 DRBA studies were identified out of 79
articles in their analysis. The high proportion of NTI drugs
where DRBA was reported in the current study is unsurpris-
ing indicating that NTI is a risk factor and the challenges in
demonstrating bioequivalence for NTI products have already
been highlighted (112).
The data shows that the proportion of those drugs
showing DRBA that were NTI drugs is highest in the BCS
2 and then followed by 3 and 1 (highly soluble) classifications.
This may be expected, as highly soluble drugs are more likely
to show equivalence than BCS class 2 drugs. This is further
supported by the U.S. FDA guidelines on waiver of in vivo
BA and BE studies for immediate release solid oral dosage
forms based on BCS class 1 and 3 system and also it is
mentioned that the BCS-based biowaivers are not applicable
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for NTI drugs (and products designed to be absorbed in the
oral cavity) (113, 114).
A comparison of the relative frequency risk factors for
the studies is presented in Fig. 1. These are shown based on
their pediatric BCS and non-NTI and NTI classification to
identify where risks were most prevalent. Fig. 1 demonstrates
that BCS class 2 drugs occupy the largest percentage of the
DRBA cases where risk factors of age-related absorption
effect, drug substance/drug product effect, and high inter- and
intra-variabilities are identified.
DISCUSSION
From Fig. 1, it is evident that age-related absorption risk
factors for DRBAwere mainly attributed to BCS class 2 non-
NTI drugs (rifampicin, indinavir, efavirenz, pyrimethamine,
lopinavir, ritonavir) and NTI drugs (e.g., carbamazepine,
cyclosporin, phenytoin, and tacrolimus). The low solubility of
BCS class 2 drugs at the site of absorption may lead to erratic
absorption of NTI drugs. Moreover, only BCS class 2 (e.g.,
phenytoin) and BCS class 3 (e.g., lamivudine) drugs were
identified as having DRBA risks due to age-related distribu-
tion effects. BCS class 2 drugs were observed at higher
frequency for both non-NTI and NTI drugs for age-related
metabolism risk factors. Interestingly, not a single case study
or risk factor that related to excretion was found in the
pediatric population.
Interestingly, drug substance-related risk factors were ob-
served most often in BCS class 2 (non-NTI (n = 1); NTI (n = 2))
drugs. The differences in BE results due to drug products are seen
at the highest frequency with both BCS class 2 categories for NTI
drugs (n = 3 for BCS class 2). Moreover, both NTI and non-NTI
BCS class 2 and 3 drugs showed DRBA due to disease
progressions and other disease-related effects. Surprisingly, BCS
class 1 NTI drugs (e.g., levothyroxine) despite having good
solubility and permeability were also found to result in DRBA in
a pediatric population although in this study, the claim of a
difference in bioequivalence was based on the pharmacodynamic
endpoint (thyroid-stimulating hormones) with smaller observed
differences in the levothyroxine exposure. This is further
supported by literature studies conducted for levothyroxine
products in healthy or diseased adults (111, 115), and it is worth
noting that the evidence of DRBA is not specific to the pediatric
population. The poor stability of levothyroxine sodium tablets has
been highlighted as they have been recalled many times since
their 1955 introduction to the US market (116).
BCS class 2 (n = 6 for non-NTI and n = 2 for NTI drugs) and
BCS class 3 (n = 2 for non-NTI) contributed notably for the
observed inter- and intra-individual variations resulting in DRBA.
The reason for inter- and intra-individual variations could be due to
the physiological complexity of the GI tract and the physicochem-
ical properties of the drug substance. The inter- and intra-individual
variations in PK parameters are higher in pediatric population as
compared to adults (92) due to the influence of growth,maturation,
diurnal variations, pharmacogenetic reasons, the pre-systemic
metabolism of the drug substance, etc. (48, 61, 117). The variations
in PK parameters could be minimized by increasing the study
power to > 80% and conducting a two-way, crossover single dose
study (118). Our results indicated that low sample size and poor
study design contributed as risk factors for DRBA results.
Table V. BCS Classification of Drugs According to Adult and Provisional Pediatric BCS System
Drugs showing DRBA Adult BCS class Pediatric BCS class Type of study Representative reference(s)
Carbamazepine 2 2 Relative BA (48)
Cyclosporine 2 2 Relative BA (57)
Efavirenz 2 2 Relative BA (43)
Emtricitabine 1 1* Relative BA (44)
Hydrocortisone 1 3/4# Relative BA (39)
Indinavir 2/4 2/4* Relative BA (41)
Lamivudine 3 3 Relative BA (8, 64)




Lopinavir 2 2 Relative BA (66, 106)
6-Mercaptopurine 4 2# Relative BA (63)
Nevirapine 2 2 Relative BA (58)
Phenytoin 2 2 Relative BA (34, 49)
Pyrimethamine 4 2# Relative BA (42)
Ritonavir 2 2 Relative BA (66, 106)
Rifampicin 2 2 Relative BA (51)
Stavudine 3 3 Relative BA (64)
Sulfadoxine 3/1 3/1* Relative BA (42)




Vitamin E Not classified Not classified Relative BA (107)
*Drug BCS class in pediatric is assumed to be same as that of adult BCS class where no provisional pediatric BCS class has been assigned for
these drugs
# 4 Drugs exhibit BCS class shift (2 favorable (BCS 4 to 2) and 2 non-favorable shift (BCS 1 to 3 and BCS 3 to 4)). Drugs name in bold are NTI
drugs otherwise non-NTI class
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The collated risk factors resulting in DRBAwill need to be
further evaluated but could potentially serve as checkpoints
during innovative pediatric formulation development, optimiza-
tion of the prediction of a pediatric dose, and the extrapolation of
BE results based on the clinical studies in adults. However, it
should also be borne in mind that DRBA due to the aforemen-
tioned risk factors does not mean therapeutic inequivalence of
pediatric medicines (119). If the final or to-be-marketed pediatric
formulation is used in the pivotal pediatric clinical study for an
innovator product, a BE/relative BA study for this product is not
necessary. Any change to the formulation utilized in the pivotal
study may trigger a clinical bridging study. It was not possible to
generate sufficient data to stratify findings into subsets of the
pediatric population (neonates, infants, children, and adoles-
cents), yet this would be useful and additional data is needed to
fully understand how risks of DRBA change with age within the
pediatric population. Further work is warranted to also compare
the magnitude of differences observed for the BE or relative BA
data identified from the pediatric population with similar data
from the adult population to fully evaluate the limitations of using
adult data to predict the PK in pediatric populations.
CONCLUSION
Adatabase containing clinical studies on BE or relative BA
in pediatrics has been developed and putative risk factors
resulting in different relative BA are summarized. Only two
publications were found that claimed to contain failed bioequiv-
alence studies in a pediatric population. The vast majority of
pediatric data comes from relative bioavailability studies of
different formulations. Analysis of the developed database has
highlighted that particular care is needed for BCS class 2 drugs
when assessing BE in pediatrics. Additional work is warranted
to use in vitro and in silicomodels for evaluating subtle changes
in GI physiology that can affect the absorption of drugs in
pediatric populations, particularly GI volume, motility, and
transit times.
SUPPLEMENTARY INFORMATION
The online version contains supplementary material
available at https://doi.org/10.1208/s12248-021-00592-y.
ACKNOWLEDGEMENTS
GP and HKB are grateful to U.S. FDA members for
valuable contribution in providing useful comments and
advice on this manuscript.
FUNDING
This review work is carried out by the University of
Birmingham under the project “Research Proposal to better
understand riskmitigation in theevaluationof relativebioavailability
of pediatric generic products” funded by U.S. FDA through FDA
BAA-17-00123 (Pediatric Generic Contract). Dr. Youssef Mousa
was supported by an appointment to the Research Participation
Program at CDER, administered by the Oak Ridge Institute for
Science andEducation (ORISE) through an interagency agreement
between the U.S. Department of Energy and the FDA.
DECLARATIONS
Conflict of Interest The authors declare no competing interests.
Disclaimer The opinions expressed in this article are those of the
authors and should not be interpreted as the position of the U.S.
FDA and the cases being presented do not imply FDA’s
endorsement of the products.
Fig. 1. Bar chart showing the number of clinical trials involving non-NTI or NTI drugs
under each risk factors analyzed
   57 Page 8 of 12 The AAPS Journal          (2021) 23:57 
Open Access This article is licensed under a Creative
Commons Attribution 4.0 International License, which per-
mits use, sharing, adaptation, distribution and reproduction in
any medium or format, as long as you give appropriate credit
to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article
are included in the article's Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material
is not included in the article's Creative Commons licence and
your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
REFERENCES




2. USFDA. 505(j)(8)(B)(ii), (C) of the FD&C Act; 21 CFR
Available from: https://www.accessdata.fda.gov/scripts/cdrh/
cfdocs/cfcfr/CFRSearch.cfm?fr=329.100. Accessed March 2021.
3. USFDA. Draft Guidance for Industry: Bioavailability Studies
Submitted in NDAs or INDs—General Considerations. 2019
Available from: https://www.fda.gov/regulatory-information/
search-fda-guidance-documents/bioavailability-studies-submit-
ted-ndas-or- inds-genera l -considerat ions . Accessed
March 2021.
4. Ricci BM. Bridging studies in support of oral pediatric
formulation development. Int J Pharm. 2013;457(1):323–6.
https://doi.org/10.1016/j.ijpharm.2013.07.074.
5. Makhlouf FT, Grosser SC, Schuirmann DJ. Basic statistical
considerations. In: Yu LX, Li BV, editors. FDA bioequivalence
standards. New York, NY: Springer New York; 2014. p. 55–93.
6. Batchelor HK, Fotaki N, Klein S. Paediatric oral
biopharmaceutics: key considerations and current challenges.
Adv Drug Deliv Rev. 2014;73:102–26. https://doi.org/10.1016/
j.addr.2013.10.006.
7. Burckart GJ. Clinical pharmacology and biopharmaceutic
considerations in pediatric global drug development. Am
Pharm Rev. 2009;12(6):28–32.
8. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga
M, Bakeera-Kitaka S, et al. Pharmacokinetics of antiretroviral
drug varies with formulation in the target population of
children with HIV-1. Clin Pharmacol Ther. 2012;91(2):272–80.
https://doi.org/10.1038/clpt.2011.225.
9. Crémieux AC, Katlama C, Gillotin C, Demarles D, Yuen GJ,
Raffi F. A comparison of the steady-state pharmacokinetics
and safety of abacavir, lamivudine, and zidovudine taken as a
triple combination tablet and as abacavir plus a lamivudine-
zidovudine double combination tablet by HIV-1-infected
adults. Pharmacotherapy. 2001;21(4):424–30. https://doi.org/
10.1592/phco.21.5.424.34497.
10. Adkison K, Wolstenholme A, Lou Y, Zhang Z, Eld A, Perger
T, et al. Effect of sorbitol on the pharmacokinetic profile of
lamivudine oral solution in adults: an open-label, randomized
study. Clin Pharmacol Ther. 2018;103(3):402–8. https://doi.org/
10.1002/cpt.943.
11. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA,
Knipp GT. Summary of the national institute of child health and
human development-best pharmaceuticals for children act pediatric
formulation initiatives workshop-pediatric biopharmaceutics classifi-
cation system working group. Clin Ther. 2012;34(11):S11–24. https://
doi.org/10.1016/j.clinthera.2012.09.014.
12. Batchelor H, Ernest T, Flanagan T, Klein S, Turner R, Fotaki
N, et al. Towards the development of a paediatric
biopharmaceutics classification system: results of a survey of
experts. Int J Pharm. 2016;511(2):1151–7. https://doi.org/
10.1016/j.ijpharm.2016.06.115.
13. Charoo NA, Cristofoletti R, Dressman JB. Risk assessment for
extending the biopharmaceutics classification system-based
biowaiver of immediate release dosage forms of fluconazole
in adults to the paediatric population. J Pharm Pharmacol.
2015;67(8):1156–69. https://doi.org/10.1111/jphp.12411.
14. Delmoral-sanchez JM, Gonzalez-alvarez I, Gonzalez-alvarez
M, Navarro A, Bermejo M. Classification of WHO essential
oral medicines for children applying a provisional pediatric
biopharmaceutics classification system. Pharmaceutics.
2019;11(11). https://doi.org/10.3390/pharmaceutics11110567.
15. Gandhi SV, Rodriguez W, Khan M, Polli JE. Considerations
for a pediatric biopharmaceutics classification system (BCS):
appl icat ion to five drugs . AAPS PharmSciTech.
2014;15(3):601–11. https://doi.org/10.1208/s12249-014-0084-0.
16. Aburub A, Sperry DC, Bhattachar S, Lobo E, Ding X, Rose
JP. Relative bioavailability risk assessment: a systematic
approach to assessing in vivo risk associated with CM&C-
related changes. J Pharm Sci. 2019;108(1):8–17. https://doi.org/
10.1016/j.xphs.2018.07.012.
17. Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg
DR, Kroetz DL. Steady state bioequivalence of generic and
innovator formulations of stavudine, lamivudine, and nevira-
pine in HIV-infected Ugandan adults. PLoS One.
2008;3(12):e3981. https://doi.org/10.1371/journal.pone.0003981.
18. Bedding A. Design and analysis of bioavailability and bio-
equivalence studies (Third Edition), Shein-Chung Chow, Jen-
pei Liu (2008) ISBN: 1584886684; 760 pages; $99.95, £63.99
Chapman and Hall/CRC; http://www.crcpress.com. Pharma-
ceutical Statistics. 2012;11(1):86-. 10.1002/pst.475.
19. PubMed. https://www.ncbi.nlm.nih.gov/pubmed/. Accessed
Jan 2021.
20. The Cochrane Library. https://www.cochranelibrary.com. Accessed
Jan 2021.
21. Google Scholar https://www.google.com/. Accessed Jan 2021.
22. van der Meersch A, Dechartres A, Ravaud P. Quality of
reporting of bioequivalence trials comparing generic to brand
name drugs: a methodological systematic review. PLoS One.
2011;6(8):e23611. https://doi.org/10.1371/journal.pone.0023611.
23. Kaur P, Jiang X, Stier E. Analysis of non-pivotal bioequiva-
lence studies submitted in abbreviated new drug submissions
for delayed-release drug products. J Pharm Pharm Sci.
2017;20:252–7. https://doi.org/10.18433/j39s6z.
24. Curtis JJ, Group ftC-S. Lack of bioequivalence of two
Sandimmune® cyclosporine formulations in renal transplant
patients who absorb cyclosporine poorly. Transplantation.
1998;65(12):S65.
25. Meyer MC, Straughn AB, Jarvi EJ, Wood GC, Pelsor FR,
Shah VP. The bioinequivalence of carbamazepine tablets with
a history of clinical failures. Pharm Res. 1992;9(12):1612–6.
https://doi.org/10.1023/A:1015872626887.
26. Carswell JM, Gordon JH, Popovsky E, Hale A, Brown RS.
Generic and brand-name L-thyroxine are not bioequivalent for
children with severe congenital hypothyroidism. J Clin
Endocrinol Metab. 2013;98(2):610–7. https://doi.org/10.1210/
jc.2012-3125.
27. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant
JR, et al. DrugBank 5.0: a major update to the DrugBank
database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–d82.
https://doi.org/10.1093/nar/gkx1037.
28. Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F,
Schuirmann DJ, et al. Novel bioequivalence approach for
narrow therapeutic index drugs. Clin Pharmacol Ther.
2015;97(3):286–91. https://doi.org/10.1002/cpt.28.
29. U.S.FDA. Product-specific guidances for generic drug devel-
opment. Available from: https://www.accessdata.fda.gov/
scripts/cder/psg/index.cfm. Accessed March 2021.
30. NICHD-FDA. Intra-agency agreement between the Eunice
Kennedy Shriver National Institute of Child Health and
Human Development (NICHD) and the U.S. Food and Drug
Administration (FDA) Oral Formulations Platform—Report
1. 2014; Available from: https://www.nichd.nih.gov/sites/
   57 Page 9 of 12The AAPS Journal          (2021) 23:57 
default/files/inline-files/Formulations_Platform_Report1.pdf.
Accessed March 2021.
31. Shawahna R. Pediatric biopharmaceutical classification system:
using age-appropriate initial gastric volume. AAPS J.
2016;18(3):728–36. https://doi.org/10.1208/s12248-016-9885-2.
32. Acott PD, Crocker JF, Renton KW. Evaluation of perfor-
mance factors affecting two formulations of cyclosporine in
pediatric renal transplant patients. Transplant Proc.
2 0 0 6 ; 3 8 ( 9 ) : 2 8 3 5 – 4 1 . h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 /
j.transproceed.2006.08.096.
33. Crocker J, Renton K, Wade A, McLellan H, Acott P. Acute
allograft rejection following conversion to a new cyclosporine
formulation in pediatric renal transplant patients. Transplant
Proc. 1998;30(5):2002–5. https://doi.org/10.1016/s0041-
1345(98)00512-0.
34. Fukuyama Y, Kitahara H, Goto T. Comparative study of
bioavailabilities of different phenytoin preparations. Brain
Dev. 1982;4(1):35–43. https://doi.org/10.1016/S0387-
7604(82)80099-5.
35. Jacobo-Cabral CO, García-Roca P, Reyes H, Lozada-Rojas L,
Cruz-Antonio L, Medeiros M, et al. Limustin®, a non-
innovator tacrolimus formulation, yields reduced drug expo-
sure in pediatric renal transplant recipients. Pediatr Trans-
plant. 2014;18(7):706–13. https://doi.org/10.1111/petr.12335.
36. Kabasakul SC, Clarke M, Kane H, Karsten J, Clark G.
Comparison of Neoral and Sandimmun cyclosporin A phar-
macokinetic profiles in young renal transplant recipients.
Pediatr Nephrol. 1997;11(3):318–21. https://doi.org/10.1007/
s004670050284.
37. Medeiros M, Gómez AC, Urizar JP, Campos-Sepúlveda AE,
Saldaña IM, Ramírez LE, et al. Bioavailability of two oral
formulations of cyclosporin A in uremic children before renal
transplantation. Pediatr Transplant. 1998;2(2):145–9.
38. Melter M, Rodeck B, Kardorff R, Hoyer PF, Brodehl J.
Pharmacokinetics of cyclosporine in pediatric long-term liver
transplant recipients converted from Sandimmun to Neoral.
Transpl Int. 1997;10(6):419–25. https://doi.org/10.1007/
s001470050080.
39. Merke DP, Cho D, Anton Calis K, Keil MF, Chrousos GP.
Hydrocortisone suspension and hydrocortisone tablets are not
bioequivalent in the treatment of children with congenital
adrenal hyperplasia. J Clin Endocrinol Metab. 2001;86(1):441–
5. https://doi.org/10.1210/jcem.86.1.7275.
40. Matsukura M, Ikeda T, Higashi A, Matsuda I. Relative
bioavailability of two different phenytoin preparations. Dev
Pharmacol Ther. 1984;7:160–8. https://doi.org/10.1159/
000457159.
41. Mueller BU, Sleasman J, Nelson RP, Smith S, Deutsch PJ, Ju
W, et al. A phase I/II study of the protease inhibitor indinavir
in children with HIV infection. Pediatrics. 1998;102(1):101–9.
https://doi.org/10.1542/peds.102.1.101.
42. Salman S, Griffin S, Kose K, Pitus N, Winmai J, Moore B, et al.
Pharmacokinetic properties of conventional and double-dose
sulfadoxine-pyrimethamine given as intermittent preventive
treatment in infancy. Antimicrob Agents Chemother.
2011;55(4):1693–700. https://doi.org/10.1128/aac.01075-10.
43. ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V,
Beijnen JH, Kuijpers TW, et al. A pharmacokinetic and
pharmacogenetic study of efavirenz in children: dosing guide-
lines can result in subtherapeutic concentrations. Antivir Ther.
2008;13(6):779–87.
44. Wang LH, Wiznia AA, Rathore MH, Chittick GE, Bakshi SS,
Emmanuel PJ, et al. Pharmacokinetics and safety of single oral
doses of emtricitabine in human immunodeficiency virus-
infected children. Antimicrob Agents Chemother.
2004;48(1):183–91. https://doi.org/10.1128/aac.48.1.183-
191.2004.
45. Bökenkamp A, Offner G, Hoyer PF, Vester U, Wonigeit K,
Brodehl J. Improved absorption of cyclosporin A from a new
microemulsion formulation: implications for dosage and mon-
itoring. Pediatr Nephrol. 1995;9(2):196–8. https://doi.org/
10.1007/bf00860745.
46. Fu LW, Yang LY, Chen WP, Lin CY. Cyclosporin pharmaco-
kinetics following administration of capsules and Neoral in
paediatric patients with lupus nephritis. Br J Clin Pharmacol.
1997 ; 44 (2 ) : 125–7 . h t tp s : / / do i . o rg / 10 . 1046 / j . 1365 -
2125.1997.00634.x.
47. Best B, Capparelli E, Diep H, Rossi S, Farrell M, Williams E,
et al. Pharmacokinetics of lopinavir/ritonavir crushed versus
whole tablets in children. J Acquir Immune Defic Syndr
(1999 ) . 2011 ; 58 : 3 85–91 . h t tp s : / / do i . o rg / 10 . 1097 /
QAI.0b013e318232b057.
48. Camfield P, Hwang P, Camfield C, Fraser A, Soldin S. al-
Quadah AK. The pharmacology of chewable versus regular
carbamazepine in chronically treated children with epilepsy.
Can J Neurol Sci Le journal canadien des sciences
neurologiques. 1992;19(2):204–7.
49. Hodges S, Forsythe WI, Gillies D, Remington H, Cawood A.
Bio-availability and dissolution of three phenytoin prepara-
tions for children. Dev Med Child Neurol. 1986;28(6):708–12.
https://doi.org/10.1111/j.1469-8749.1986.tb03921.x.
50. Portman RJ, Meier-Kriesche HU, Swinford R, Brannan P,
Kahan BD. Reduced variability of Neoral pharmacokinetic
studies in pediatric renal transplantation. Pediatr Nephrol.
2000;15(1):2–6. https://doi.org/10.1007/s004670000435.
51. McIlleron H, Hundt H, Smythe W, Bekker A, Winckler J, van
der Laan L, et al. Bioavailability of two licensed paediatric
rifampicin suspensions: implications for quality control
programmes. Int J Tuberc Lung Dis. 2016;20(7):915–9. https://
doi.org/10.5588/ijtld.15.0833.
52. Reding R, Sokal E, Paul K, Janssen M, Evrard V, Wilmotte L,
et al. Efficacy and pharmacokinetics of tacrolimus oral
suspension in pediatric liver transplant recipients. Pediatr
Transplant. 2002;6(2):124–6. https://doi.org/10.1034/j.1399-
3046.2002.01052.x.
53. van Mourik IDM, Thomson M, Kelly DA. Comparison of
pharmacokinetics of neoral and sandimmune in stable pediat-
ric liver transplant recipients. Liver Transplant Surg.
1999;5(2):107–11. https://doi.org/10.1002/lt.500050203.
54. Krmar RT, Wuhl E, Ding R, Aulmann M, Schärer K.
Pharmacokinetics of a new microemulsion formulation of
cyclosporin A (Neoral) in young patients after renal trans-
plantation. Transpl Int. 1996;9(5):476–80. https://doi.org/
10.1007/BF00336825.
55. Dunn S, Cooney G, Sommerauer J, Lindsay C, McDiarmid S,
Wong RL, et al. Pharmacokinetics of an oral solution of the
microemulsion formulation of cyclosporine in maintenance
pediatric liver transplant recipients. Transplantation.
1997;63(12):1762–7.
56. Alvarez F, Atkison PR, Grant DR, Guilbault N, Jones AB,
Kim PS, et al. NOF-11: a one-year pediatric randomized
double-blind comparison of neoral versus sandimmune in
orthotopic l iver transplantat ion. Transplantat ion.
2000;69(1):87–92. https://doi.org/10.1097/00007890-200001150-
00016.
57. Kelles A, Herman J, Budya Tjandra-Maga T, Van Damme-
Lombaerts R. Sandimmune® to Neoral® conversion and value
of abbreviated AUC monitoring in stable pediatric kidney
transplant recipients. Pediatr Transplant. 1999;3(4):282–7.
https://doi.org/10.1034/j.1399-3046.1999.00058.x.
58. Chokephaibulkit K, Cressey TR, Capparelli E, Sirisanthana V,
Muresan P, Hongsiriwon S, et al. Pharmacokinetics and safety
of a new paediatric fixed-dose combination of zidovudine/
lamivudine/nevirapine in HIV-infected children. Antivir Ther.
2011;16(8):1287–95. https://doi.org/10.3851/IMP1931.
59. Vondrak K, Dhawan A, Parisi F, Grenda R, Debray D, Marks
SD, et al. Comparative pharmacokinetics of tacrolimus in de
novo pediatric transplant recipients randomized to receive
immediate- or prolonged-release tacrolimus. Pediatr Trans-
plant. 2018;22(8):e13289. https://doi.org/10.1111/petr.13289.
60. Ellis JC, L’Homme RF, Ewings FM, Mulenga V, Bell F,
Chileshe R, et al. Nevirapine concentrations in HIV-infected
children treated with divided fixed-dose combination antire-
troviral tablets in Malawi and Zambia. Antivir Ther.
2007;12(2):253–60.
61. Eeg-Olofsson O, Nilsson HL, Tonnby B, Arvidsson J, Grahn
PA, Gylje H, et al. Diurnal variation of carbamazepine and
carbamazepine-10,11-epoxide in plasma and saliva in children
with epilepsy: a comparison between conventional and slow-
   57 Page 10 of 12 The AAPS Journal          (2021) 23:57 
release formulations. J Child Neurol. 1990;5(2):159–65. https://
doi.org/10.1177/088307389000500219.
62. Vanprapar N, Cressey TR, Chokephaibulkit K, Muresan P,
Plipat N, Sirisanthana V, et al. A chewable pediatric fixed-dose
combination tablet of stavudine, lamivudine, and nevirapine:
pharmacokinetics and safety compared with the individual
liquid formulations in human immunodeficiency virus-infected
children in Thailand. Pediatr Infect Dis J. 2010;29(10):940–4.
https://doi.org/10.1097/INF.0b013e3181e2189d.
63. Tolbert JA, Bai S, Abdel-Rahman SM, August KJ, Weir SJ,
Kearns GL, et al. Pharmacokinetics of two 6-mercaptopurine
liquid formulations in children with acute lymphoblastic
leukemia. Pediatr Blood Cancer. 2017;64(8):e26465. https://
doi.org/10.1002/pbc.26465.
64. Mukherjee A, Singla M, Velpandian T, Sirohiwal A, Vajpayee
M, Singh R, et al. Pharmacokinetics of nevirapine, stavudine
and lamivudine in Indian HIV-infected children receiving
generic fixed dose combinat ions. Indian Pediatr.
2014;51(3):191–7. https://doi.org/10.1007/s13312-014-0382-3.
65. Salem AH, Fletcher CV, Brundage RC. Pharmacometric
characterization of efavirenz developmental pharmacokinetics
and pharmacogenetics in human immunodeficiency virus
infected children. Antimicrob Agents Chemother.
2013:AAC.01738-13. https://doi.org/10.1128/aac.01738-13.
66. Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R,
Namuddu R, et al. The pharmacokinetics and acceptability of
lopinavir/ritonavir minitab sprinkles, tablets, and syrups in
african HIV-infected children. J Acquir Immune Defic Syndr.
2 0 1 4 ; 6 6 ( 2 ) : 1 4 8 – 5 4 . h t t p s : / / d o i . o r g / 1 0 . 1 0 9 7 /
qai.0000000000000135.
67. Cassio A, Monti S, Rizzello A, Bettocchi I, Baronio F,
D’Addabbo G, et al. Comparison between liquid and tablet
formulations of levothyroxine in the initial treatment of
congenital hypothyroidism. J Pediatr. 2013;162(6):1264–9,
9.e1-2. https://doi.org/10.1016/j.jpeds.2012.11.070.
68. Pollock L, Else L, Poerksen G, Molyneux E, Moons P, Walker
S, et al. Pharmacokinetics of nevirapine in HIV-infected
children with and without malnutrition receiving divided adult
fixed-dose combination tablets. J Antimicrob Chemother.
2009;64(6):1251–9. https://doi.org/10.1093/jac/dkp358.
69. Allegaert K, van den Anker J. Neonatal drug therapy: the first
frontier of therapeutics for children. Clin Pharmacol Ther.
2015;98(3):288–97. https://doi.org/10.1002/cpt.166.
70. Bowles A, Keane J, Ernest T, Clapham D, Tuleu C. Specific
aspects of gastro-intestinal transit in children for drug delivery
design. Int J Pharm. 2010;395(1–2):37–43. https://doi.org/
10.1016/j.ijpharm.2010.04.048.
71. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn.
Adv Drug Deliv Rev. 2003;55(5):667–86. https://doi.org/
10.1016/s0169-409x(03)00030-9.
72. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical
dosage forms through the small intestine. Gut. 1986;27(8):886–
92. https://doi.org/10.1136/gut.27.8.886.
73. Gómez Acotto C, Antonelli C, Flynn D, McDaid D, Roldán
EJ. Upper gastrointestinal tract transit times of tablet and
drinkable solution formulations of alendronate: a bioequiva-
lence and a quantitative, randomized study using video
deglutition. Calcif Tissue Int. 2012;91(5):325–34. https://
doi.org/10.1007/s00223-012-9639-9.
74. Thyssen A, Solanki B, Gonzalez M, Leitz G, Treem W,
Mannaert E. Pharmacokinetics of rabeprazole granules versus
tablets, and the effect of food on the pharmacokinetics of
rabeprazole granules in healthy adults—cross-study compari-
son. Clin Pharmacol Drug Dev. 2014;3(5):406–16. https://
doi.org/10.1002/cpdd.118.
75. Tirpude RN, Puranik PK. Rabeprazole sodium delayed-release
multiparticulates: effect of enteric coating layers on product
performance. J Adv Pharm Technol Res. 2011;2(3):184–91.
https://doi.org/10.4103/2231-4040.85539. Accessed Dec 2020.
76. Organization WH. Proposal to waive in vivo bioequivalence
requirements for WHO model list of essential medicines
immediate-release, solid oral dosage forms. WHO Technical
Report Series, No. 937, 2006, Annex 8. 2006. Accessed
March 2021
77. Shugarts S, Benet LZ. The role of transporters in the
pharmacokinetics of orally administered drugs. Pharm Res.
2009;26(9):2039–54. https://doi.org/10.1007/s11095-009-9924-0.
78. Wu CY, Benet LZ. Predicting drug disposition via application
of BCS: transport/absorption/ elimination interplay and devel-
opment of a biopharmaceutics drug disposition classification
system. Pharm Res. 2005;22(1):11–23. https://doi.org/10.1007/
s11095-004-9004-4.
79. Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key
considerations. Br J Clin Pharmacol. 2015;79(3):395–404.
https://doi.org/10.1111/bcp.12267.
80. Ehrnebo M, Agurell S, Jalling B, Boréus LO. Age differences
in drug binding by plasma proteins: studies on human foetuses,
neonates and adults. Eur J Clin Pharmacol. 1971;3(4):189–93.
https://doi.org/10.1007/bf00565004.
81. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the
newborn infant. A physiologic explanation of its toxicity when
given in excessive doses. N Engl J Med. 1960;262:787–94.
https://doi.org/10.1056/nejm196004212621601.
82. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave
JP, et al. Response to antiretroviral treatment in HIV-1-
infected individuals with allelic variants of the multidrug
resistance transporter 1: a pharmacogenetics study. Lancet.
2002;359(9300):30–6. https: / /doi .org/10.1016/s0140-
6736(02)07276-8.
83. Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd
JC. Lower phenytoin serum levels in persons switched from
brand to generic phenytoin. Neurology. 2004;63(8):1494–6.
https://doi.org/10.1212/01.Wnl.0000142091.47698.A2.
84. Soryal I, Richens A. Bioavailability and dissolution of propri-
etary and generic formulations of phenytoin. J Neurol
Neurosurg Psychiatry. 1992;55(8):688–91. https://doi.org/
10.1136/jnnp.55.8.688. Accessed Dec 2020
85. Suthisisang C, Payakachat N, Chulavatnatol S, Towanabut S.
Bioavailability of phenytoin sodium capsules available in
Thailand. Part II: in vivo study. J Med Assoc Thail.
1998;81(1):64–70.
86. Rosenbaum DH, Rowan AJ, Tuchman L, French JA. Com-
parative bioavailability of a generic phenytoin and Dilantin.
Epilepsia. 1994;35(3):656–60. https://doi.org/10.1111/j.1528-
1157.1994.tb02487.x.
87. Tsai JJ, Lai ML, Yang YH, Huang JD. Comparison on
bioequivalence of four phenytoin preparations in patients with
multiple-dose treatment. J Clin Pharmacol. 1992;32(3):272–6.
https://doi.org/10.1002/j.1552-4604.1992.tb03836.x.
88. NHS UK. Phenytoin Available from: https://www.nhs.uk/med-
icines/phenytoin/.
89. U.S.FDA. Product specific guidance for phenytoin oral
s u s p e n s i o n 2 0 1 7 ; Av a i l a b l e f r o m : h t t p s : / /
www. a c c e s s d a t a . f d a . g o v / d r u g s a t f d a _ d o c s / p s g /
Phenytoin_oral%20suspension_RLD%20008762_RV03-
17.pdf.
90. Patel RB, Rogge MC, Selen A, Goehl TJ, Shah VP, Prasad
VK, et al. Bioavailability of hydrocortisone from commercial
20-mg tablets. J Pharm Sci. 1984;73(7):964–6. https://doi.org/
10.1002/jps.2600730726.
91. Henwood SQ, Liebenberg W, Tiedt LR, Lötter AP, de Villiers
MM. Characterization of the solubility and dissolution proper-
ties of several new rifampicin polymorphs, solvates, and
hydrates. Drug Dev Ind Pharm. 2001;27(10):1017–30. https://
doi.org/10.1081/DDC-100108364.
92. Uematsu FTS, Fukuyama Y, Yakou S. A clinico-
pharmacological study of a phenytoin granule preparation in
epileptic children. Brain Dev. 1982;14(3):324–32.
93. Papadatou-Soulou E, Mason J, Parsons C, Oates A,
Thyagarajan M, Batchelor HK. Magnetic resonance imaging
quantification of gastrointestinal liquid volumes and distribu-
tion in the gastrointestinal tract of children. Mol Pharm.
2 0 1 9 ; 1 6 ( 9 ) : 3 8 9 6 – 9 0 3 . h t t p s : / / d o i . o r g / 1 0 . 1 0 2 1 /
acs.molpharmaceut.9b00510.
94. U.S.FDA. General clinical pharmacology considerations for
pediatric studies for drugs and biological products guidance for
industry. 2014; Available from: https://www.fda.gov/media/
90358/download.
   57 Page 11 of 12The AAPS Journal          (2021) 23:57 
95. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR.
Enteropathy associated with the acquired immunodeficiency
syndrome. Ann Intern Med. 1984;101(4):421–8. https://doi.org/
10.7326/0003-4819-101-4-421.
96. Crakes KR, Jiang G. Gut microbiome alterations during HIV/
SIV infection: implications for HIV cure. Front Microbiol.
2019;10:1104. https://doi.org/10.3389/fmicb.2019.01104.
97. Brenchley JM, Douek DC. HIV infection and the gastrointes-
tinal immune system. Mucosal Immunol. 2008;1(1):23–30.
https://doi.org/10.1038/mi.2007.1.
98. Poles MA, Fuerst M, McGowan I, Elliott J, Rezaei A, Mark D,
et al. HIV-related diarrhea is multifactorial and fat malabsorp-
tion is commonly present, independent of HAART. Am J
Gastroenterol. 2001;96(6):1831–7. https://doi.org/10.1111/
j.1572-0241.2001.03879.x.
99. Oude Munnink BB, Canuti M, Deijs M, de Vries M, Jebbink
MF, Rebers S, et al. Unexplained diarrhoea in HIV-1 infected
individuals. BMC Infect Dis. 2014;14(1):22. https://doi.org/
10.1186/1471-2334-14-22.
100. Guarino A, Bruzzese E, De Marco G, Buccigrossi V. Manage-
ment of gastrointestinal disorders in children with HIV
infection. Pediatr Drugs. 2004;6(6):347–62. https://doi.org/
10.2165/00148581-200406060-00003.
101. Whitington PF, Emond JC, Whitington SH, Broelsch CE,
Baker AL. Small-bowel length and the dose of cyclosporine in
children after liver transplantation. N Engl J Med.
1 9 9 0 ; 3 2 2 ( 1 1 ) : 7 3 3 – 8 . h t t p s : / / d o i . o r g / 1 0 . 1 0 5 6 /
nejm199003153221105.
102. Van Peer A. Variability and impact on design of bioequiva-
lence studies. Basic Clin Pharmacol Toxicol. 2010;106(3):146–
53. https://doi.org/10.1111/j.1742-7843.2009.00485.x.
103. Naicker D, Reed PW, Ronaldson J, Kara T, Wong W, Prestidge
C. Nationwide conversion to generic tacrolimus in pediatric
k idney t ransp lan t rec ip i en t s . Ped ia t r Nephro l .
2017;32(11):2125–31. https://doi.org/10.1007/s00467-017-3707-3.
104. van Stralen JP. The clinical impact of switching attention deficit
hyperactivity disorder patients from OROS(®)-MPH to Novo-
MPH ER-C(®): a paediatric practice review. Paediatr Child
Health. 2013;18(2):70–3. https://doi.org/10.1093/pch/18.2.70.
105. Lomenick JP, Wang L, Ampah SB, Saville BR, Greenwald FI.
Generic levothyroxine compared with synthroid in young
children with congenital hypothyroidism. J Clin Endocrinol
Metab. 2013;98(2):653–8. https://doi.org/10.1210/jc.2012-3558.
106. PENTA. Once vs. twice-daily lopinavir/ritonavir in HIV-1-
infected children. AIDS. 2015;29(18):2447–57. https://doi.org/
10.1097/qad.0000000000000862.
107. Jacquemin E, Hermeziu B, Kibleur Y, Friteau I, Mathieu D, Le
Coz F, et al. Bioavailability of oral vitamin E formulations in
adult volunteers and children with chronic cholestasis or cystic
fibrosis. J Clin Pharm Ther. 2009;34(5):515–22. https://doi.org/
10.1111/j.1365-2710.2009.01027.x.
108. Williams HD, Trevaskis NL, Charman SA, Shanker RM,
Charman WN, Pouton CW, et al. Strategies to address low
drug solubility in discovery and development. Pharmacol Rev.
2013;65(1):315–499. https://doi.org/10.1124/pr.112.005660.
109. Cristofoletti R, Chiann C, Dressman JB, Storpirtis S. A
comparative analysis of biopharmaceutics classification system
and biopharmaceutics drug disposition classification system: a
cross-sectional survey with 500 bioequivalence studies. J
Pharm Sci. 2013;102(9):3136–44. https://doi.org/10.1002/
jps.23515.
110. Ramirez E, Laosa O, Guerra P, Duque B, Mosquera B,
Borobia AM, et al. Acceptability and characteristics of 124
human bioequivalence studies with active substances classified
according to the Biopharmaceutic Classification System. Br J
Clin Pharmacol. 2010;70(5):694–702. https://doi.org/10.1111/
j.1365-2125.2010.03757.x.
111. Hennessey JV, Burman KD, Wartofsky L. The equivalency of
two L-thyroxine preparat ions . Ann Intern Med.
1985;102(6):770–3. https://doi.org/10.7326/0003-4819-102-6-770.
112. Jiang W, Makhlouf F, Schuirmann DJ, Zhang X, Zheng N,
Conner D, et al. A bioequivalence approach for generic
narrow therapeutic index drugs: evaluation of the reference-
scaled approach and variability comparison criterion. AAPS J.
2015;17(4):891–901. https://doi.org/10.1208/s12248-015-9753-5.
Accessed Dec 2020
113. U.S.FDA. Waiver of in vivo bioavailability and bioequivalence
studies for immediate-release solid oral dosage forms based on
a biopharmaceutics classification system. Guidance for Indus-




114. Uppoor RS, Vaidyanathan J, Mehta M, Yu LX. Biowaiver and
biopharmaceutics classification system. In: Yu LX, Li BV,
editors. FDA bioequivalence standards. New York, NY:
Springer New York; 2014. p. 119–37.
115. Blakesley V, Awni W, Locke C, Ludden T, Granneman GR,
Braverman LE. Are bioequivalence studies of levothyroxine
sodium formulations in euthyroid volunteers reliable? Thyroid.
2 0 0 4 ; 1 4 ( 3 ) : 1 9 1 – 2 0 0 . h t t p s : / / d o i . o r g / 1 0 . 1 0 8 9 /
105072504773297867.
116. Hamad ML, Engen W, Morris KR. Impact of hydration state
and molecular oxygen on the chemical stability of
levothyroxine sodium. Pharm Dev Technol. 2015;20(3):314–9.
https://doi.org/10.3109/10837450.2013.862635.
117. Lapeyraque AL, Kassir N, Theoret Y, Krajinovic M, Clermont
MJ, Litalien C, et al. Conversion from twice- to once-daily
tacrolimus in pediatric kidney recipients: a pharmacokinetic
and bioequivalence study. Pediatr Nephrol. 2014;29(6):1081–8.
https://doi.org/10.1007/s00467-013-2724-0.
118. Galgatte UC, Jamdade VR, Aute PP, Chaudhari PD. Study on
requirements of bioequivalence for registration of pharmaceu-
tical products in USA, Europe and Canada. Saudi Pharm J.
2014;22(5):391–402. https://doi.org/10.1016/j.jsps.2013.05.001.
119. García-Arieta A. The failure to show bioequivalence is not
evidence against generics . Br J Cl in Pharmacol .
2010 ; 70 (3 ) : 4 52–3 . h t t p s : / / do i . o rg / 1 0 . 1111 / j . 1365 -
2125.2010.03684.x.
Publisher’s Note Springer Nature remains neutral with regard
to jurisdictional claims in published maps and institutional
affiliations.
   57 Page 12 of 12 The AAPS Journal          (2021) 23:57 
